Financial Performance - Revenue for the six months ended December 31, 2025, was HK$68,131,000, a decrease of 5.9% compared to HK$72,334,000 in the previous period[5] - Gross profit for the same period was HK$41,044,000, down from HK$43,921,000, reflecting a gross margin of 60.2%[5] - Profit before taxation decreased to HK$4,556,000, compared to HK$11,987,000 in the previous period, representing a decline of 62.0%[7] - Profit for the period was HK$4,224,000, down from HK$11,637,000, marking a decrease of 63.7%[7] - Total comprehensive income for the period was a loss of HK$601,000, compared to a gain of HK$11,998,000 in the previous period[7] - Basic and diluted earnings per share decreased to HK1.13 cents from HK3.72 cents[7] - Total revenue for the Group was HK$68,131,000, a decrease of 5.5% from HK$72,334,000 in the previous year[32] - The segment result for the technology division showed a profit of HK$4,912,000 for the six months ended December 31, 2025, down from HK$11,271,000 in 2024, indicating a decline of about 56.4%[37] - The profit attributable to owners of the company for the period was HK$4,224,000, a significant decrease from HK$11,637,000 in the previous year, representing a decline of approximately 63.7%[47] Assets and Liabilities - Non-current assets as of December 31, 2025, totaled HK$87,156,000, a decrease from HK$90,228,000 as of June 30, 2025[10] - Current assets decreased to HK$203,770,000 from HK$217,347,000, reflecting a decline of 6.2%[10] - Net assets as of December 31, 2025, were HK$221,511,000, slightly down from HK$222,112,000[10] - Cash and cash equivalents at the end of the period were HK$136,036,000, compared to HK$108,890,000 at the end of the previous period[16] - Trade receivables increased from HK$19,073,000 as of June 30, 2025, to HK$8,898,000 as of December 31, 2025, indicating a significant reduction[66] - The total amount of other receivables rose from HK$23,887,000 to HK$27,688,000 during the same period[66] - The total inventory as of December 31, 2025, is HK$17,798,000, down from HK$18,770,000 as of June 30, 2025[64] - The Group's trade receivables that are neither past due nor impaired decreased from HK$18,857,000 to HK$8,828,000[73] Cash Flow and Financing - Net cash generated from operating activities increased to HK$10,135,000, up 47% from HK$6,875,000 in the previous year[16] - Net cash used in investing activities was HK$7,017,000, an increase from HK$6,553,000 in 2024[16] - The Group's finance costs decreased to HK$171,000 from HK$231,000 in the previous year[16] - The Group's tax paid was HK$650,000, compared to a tax refund of HK$2,726,000 in 2024[16] - The group had no borrowings as of December 31, 2025, and incurred finance costs of approximately HK$171,000 during the period[179] - A fundraising exercise completed in June 2024 raised approximately HK$14.8 million, intended for general working capital and potential investments[180] - The 2025 placing raised approximately HK$10.5 million from the issuance of 62,505,000 shares at a price of HK$0.172 per share, intended for general working capital and acquisition of industrial premises in Hong Kong[190] Expenses - Distribution costs for the six months ended December 31, 2025, were approximately HK$14.3 million, an increase from HK$12.3 million in 2024, attributed to higher logistics costs and foreign currency fluctuations[92] - General and administrative expenses increased by approximately 8.5% to approximately HK$24.3 million for the six months ended December 31, 2025, compared to approximately HK$22.4 million in 2024, mainly due to increased employment costs[93] Market and Economic Conditions - The UK remains the largest market for the company, although sales have decreased compared to the previous period; positive forecasts for the remainder of the fiscal year with several large contracts expected in the Healthcare sector early in 2026[166] - The company anticipates moderate but uneven global economic growth in early 2026, with the UK GDP growth projected to slow due to a softening labor market and cautious consumer spending[156] - The Eurozone outlook indicates subdued GDP growth, supported by improving household incomes but tempered by weak sentiment and limited fiscal and monetary stimulus[157] Product Development and Innovation - Multitone Nucleus™ platform through collaboration with Amazon Web Services provides a highly available emergency messaging application, enhancing market competitiveness[128] - EkoTek® product line has achieved success in the personal safety and care call market in Germany, with the launch of a new IK10-rated vandal-resistant device significantly enhancing sales advantage[134] - The company is investing in R&D for the Multitone Nucleus™ messaging solution, which will include AI-enabled features[159] - Multitone Evolve™ is undergoing final approvals and is set for a full-scale market rollout in Q2 2026, supporting communication via traditional RF networks, Wi-Fi, and Bluetooth Low Energy[163] Loan and Credit Management - The company will continue to maintain personal contact with borrowers throughout the loan duration, starting reminders about repayment approximately one month before due dates[149] - The company has established standard procedures for handling delinquent loans, including sending demand letters and potentially initiating formal legal action if necessary[150] - The company's China subsidiary has signed a loan contract with an independent third party for RMB2,500,000 at an annual interest rate of 8%[136]
看通集团(01059) - 2026 - 中期财报